Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

bioAffinity Technologies, Inc.

BIAFNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 19, 2026Accepted Nov 19, 2026, 4:30 PM ESTFiling CIK 1712762Accession 0001475597-26-000254
Share

Structured filing — 4

primary_doc.xml

Open full document ↗

Filing details

Report period
2026-09-22
Issuer
bioAffinity Technologies, Inc.
Issuer CIK
0001712762
Trading symbol
BIAF
No longer subject to Section 16
Checked

Reporting owner 1

Name
HRT FINANCIAL LP
Reporting owner CIK
0001475597
Relationship
10% owner
Address
3 WORLD TRADE CENTER, 175 GREENWICH STRE, 76TH FLOOR, NEW YORK, NY, 10007

Non-derivative transactions

Non-derivative transactions · 22 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-09-22P · Form 418,929A8.5879[F1]126,519[F8]D
Common Stock2026-09-22S · Form 47,077D8.6306[F2]126,519[F8]D
Common Stock2026-09-23P · Form 47,509A7.9123[F3]128,884[F8]D
Common Stock2026-09-23P · Form 411,002A8.1438[F4]128,884[F8]D
Common Stock2026-09-23S · Form 411,129D7.9399[F5]128,884[F8]D
Common Stock2026-09-23S · Form 410,859D8.1074[F6]128,884[F8]D
Common Stock2026-09-24P · Form 430,065A7.668[F9]131,221[F14]D
Common Stock2026-09-24S · Form 427,246D7.755[F10]131,221[F14]D
Common Stock2026-09-25P · Form 47,271A7.8065[F11]126,037[F14]D
Common Stock2026-09-25S · Form 49,111D7.8588[F12]126,037[F14]D
Common Stock2026-09-28P · Form 410,734A7.6438[F15]127,533[F23]D
Common Stock2026-09-28P · Form 42A8.09127,533[F23]D
Common Stock2026-09-28S · Form 413,856D7.5676[F16]127,533[F23]D
Common Stock2026-09-28S · Form 4152D8.1012[F17]127,533[F23]D
Common Stock2026-09-29P · Form 48,894A6.8647[F18]134,741[F23]D
Common Stock2026-09-29P · Form 413,840A7.1206[F19]134,741[F23]D
Common Stock2026-09-29S · Form 418,627D6.8259[F20]134,741[F23]D
Common Stock2026-09-29S · Form 42,201D7.0518[F21]134,741[F23]D
Common Stock2026-09-30P · Form 412,125A6.7775[F24]126,146[F28]D
Common Stock2026-09-30S · Form 420,432D6.7638[F25]126,146[F28]D
Common Stock2026-10-01P · Form 417,873A6.5436[F26]116,658[F29]D
Common Stock2026-10-01S · Form 441,529D6.4466[F27]116,658[F29]D
Table key
P · Form 4
Purchase on the market or privately
A
Acquired
D
Direct
S · Form 4
Sale on the market or privately

Derivative transactions

Derivative transactions · 6 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Warrant (rights to buy)3,645[F7]2026-09-23P · Form 41A0.322022-06-222027-06-22Common Stock0.00221,198[F8]D
Warrant (rights to buy)3,645[F7]2026-09-23S · Form 42D0.312022-06-222027-06-22Common Stock0.00441,198[F8]D
Warrant (rights to buy)3,645[F13]2026-09-24S · Form 46D0.262022-06-222027-06-22Common Stock0.01331,202[F14]D
Warrant (rights to buy)3,645[F13]2026-09-25S · Form 41D0.262022-06-222027-06-22Common Stock0.00221,202[F14]D
Warrant (rights to buy)3,645[F22]2026-09-28P · Form 42A0.382022-06-222027-06-22Common Stock0.0044913[F23]D
Warrant (rights to buy)3,645[F22]2026-09-29P · Form 41A0.322022-06-222027-06-22Common Stock0.0022986[F23]D
Table key
P · Form 4
Purchase on the market or privately
A
Acquired
D
Direct
S · Form 4
Sale on the market or privately

Footnotes

F1
Weighted average price; executed in multiple trades at prices from $8.405 to $8.74.*↩ 1
F2
Weighted average price; executed in multiple trades at prices from $8.405 to $8.74.*↩ 1
F3
Weighted average price; executed in multiple trades at prices from $7.78 to $7.995.*↩ 1
F4
Weighted average price; executed in multiple trades at prices from $8.00 to $8.80.*↩ 1
F5
Weighted average price; executed in multiple trades at prices from $7.86 to $7.99.*↩ 1
F6
Weighted average price; executed in multiple trades at prices from $8.00 to $8.84.*↩ 1
F7
Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. Underlying amounts are rounded to four decimal places.↩ 1↩ 2
F8
Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
F9
Weighted average price; executed in multiple trades at prices from $7.50 to $7.95.*↩ 1
F10
Weighted average price; executed in multiple trades at prices from $7.59 to $7.98.*↩ 1
F11
Weighted average price; executed in multiple trades at prices from $7.67 to $7.95.*↩ 1
F12
Weighted average price; executed in multiple trades at prices from $7.74 to $7.96.*↩ 1
F13
Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. Underlying amounts are rounded to four decimal places.↩ 1↩ 2
F14
Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6
F15
Weighted average price; executed in multiple trades at prices from $7.33 to $7.93.*↩ 1
F16
Weighted average price; executed in multiple trades at prices from $7.33 to $7.92.*↩ 1
F17
Weighted average price; executed in multiple trades at prices from $8.10 to $8.13.*↩ 1
F18
Weighted average price; executed in multiple trades at prices from $6.68 to $6.99.*↩ 1
F19
Weighted average price; executed in multiple trades at prices from $7.01 to $7.50.*↩ 1
F20
Weighted average price; executed in multiple trades at prices from $6.69 to $6.99.*↩ 1
F21
Weighted average price; executed in multiple trades at prices from $7.00 to $7.60.*↩ 1
F22
Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. Underlying amounts are rounded to four decimal places.↩ 1↩ 2
F23
Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10
F24
Weighted average price; executed in multiple trades at prices from $6.56 to $6.99.*↩ 1
F25
Weighted average price; executed in multiple trades at prices from $6.59 to $6.99.*↩ 1
F26
Weighted average price; executed in multiple trades at prices from $6.23 to $6.88.*↩ 1
F27
Weighted average price; executed in multiple trades at prices from $6.07 to $6.865.*↩ 1
F28
Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.↩ 1↩ 2
F29
Represents the reporting person's beneficial ownership immediately after the transaction that reduced its beneficial ownership to 10% or less of the outstanding Common Stock, ending the period in which the transactions reported on this line occurred, including transactions not reported on this form.↩ 1↩ 2

Remarks

*The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.

Signature 1

Signed
Adam Nunes
Date
2026-11-19

Company context

bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by HRT FINANCIAL LP regarding bioAffinity Technologies, Inc.Nov 19, 2026
  2. 3 filingNov 19, 2026
  3. Other EventsNov 19, 2026
  4. Other EventsNov 17, 2026
  5. Results of Operations and Financial ConditionNov 6, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.